Alnylam Pharmaceuticals (ALNY) Profit After Tax Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -29.12% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 59.34% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.44% |
| Mar 31, 2026 | 47.10% |
| Dec 31, 2025 | 37.59% |
| Sep 30, 2025 | 38.14% |
| Jun 30, 2025 | 37.95% |
| Mar 31, 2025 | 76.81% |
| Dec 31, 2024 | 39.40% |
| Sep 30, 2024 | 26.99% |
| Jun 30, 2024 | 65.70% |
| Mar 31, 2024 | 30.95% |
| Dec 31, 2023 | 19.11% |
| Sep 30, 2023 | 37.54% |
| Jun 30, 2023 | -15.48% |
| Mar 31, 2023 | 1.51% |
| Dec 31, 2022 | 8.97% |
| Sep 30, 2022 | -25.02% |
| Jun 30, 2022 | -8.12% |
| Mar 31, 2022 | -9.73% |
| Dec 31, 2021 | -6.92% |
| Sep 30, 2021 | 5.88% |